ADAR1 Capital Management »

Travere Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $771 100 7.71
2023-12-31 $899 100 8.99

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Travere Therapeutics

BlackRock
BlackRock
Armistice Capital
Deep Track Capital
Vanguard Group
Rock Springs Capital Management
Macquarie Group
Woodline Partners
State Street Corporation
Morgan Stanley
Kynam Capital Management
Emerald Advisers
Renaissance Technologies
D. E. Shaw & Co
Bank of America Corporation

View all funds holding Travere Therapeutics